NEW YORK, Aug 29 – Sequenom said Wednesday it had entered an agreement with GlaxoSmithKline to create a SNP assay portfolio that would cover the entire human genome.

"Our immediate goal is to establish a SNP assay portfolio covering all SNPs,” Allen Roses, senior vice president of genetics research at GlaxoSmithKline, said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.